JPWO2021055376A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021055376A5 JPWO2021055376A5 JP2022516442A JP2022516442A JPWO2021055376A5 JP WO2021055376 A5 JPWO2021055376 A5 JP WO2021055376A5 JP 2022516442 A JP2022516442 A JP 2022516442A JP 2022516442 A JP2022516442 A JP 2022516442A JP WO2021055376 A5 JPWO2021055376 A5 JP WO2021055376A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- pharmaceutically acceptable
- acceptable salt
- alkyl
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 122
- 150000001875 compounds Chemical class 0.000 claims 119
- 229910052736 halogen Inorganic materials 0.000 claims 87
- 150000002367 halogens Chemical class 0.000 claims 87
- 125000001424 substituent group Chemical group 0.000 claims 86
- 125000000217 alkyl group Chemical group 0.000 claims 82
- 125000000623 heterocyclic group Chemical group 0.000 claims 62
- 229910052799 carbon Inorganic materials 0.000 claims 29
- 239000000126 substance Substances 0.000 claims 28
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 239000001257 hydrogen Substances 0.000 claims 18
- 125000002619 bicyclic group Chemical group 0.000 claims 13
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 12
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 10
- 125000000304 alkynyl group Chemical group 0.000 claims 10
- 150000002431 hydrogen Chemical class 0.000 claims 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 239000011737 fluorine Substances 0.000 claims 8
- 229910052731 fluorine Inorganic materials 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 6
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 6
- 125000001188 haloalkyl group Chemical group 0.000 claims 6
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 6
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 5
- 201000004681 Psoriasis Diseases 0.000 claims 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 4
- 206010037575 Pustular psoriasis Diseases 0.000 claims 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 3
- 125000004122 cyclic group Chemical group 0.000 claims 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 229930192474 thiophene Natural products 0.000 claims 3
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 claims 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 206010015278 Erythrodermic psoriasis Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 206010018797 guttate psoriasis Diseases 0.000 claims 2
- 208000002557 hidradenitis Diseases 0.000 claims 2
- 201000007162 hidradenitis suppurativa Diseases 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000002458 infectious effect Effects 0.000 claims 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 2
- 150000002545 isoxazoles Chemical group 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 201000010914 pustulosis of palm and sole Diseases 0.000 claims 2
- 208000011797 pustulosis palmaris et plantaris Diseases 0.000 claims 2
- 150000003217 pyrazoles Chemical group 0.000 claims 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000005671 spondyloarthropathy Diseases 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 150000003536 tetrazoles Chemical class 0.000 claims 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims 2
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 1
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical compound C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 claims 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 claims 1
- YKNUXXRRPRLOBW-UHFFFAOYSA-N 1-azaspiro[3.3]heptane Chemical compound C1CCC21NCC2 YKNUXXRRPRLOBW-UHFFFAOYSA-N 0.000 claims 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims 1
- WILDQENJKOOOPR-UHFFFAOYSA-N 4,6-dihydrofuro[3,4-b]furan Chemical compound C1=2COCC=2C=CO1 WILDQENJKOOOPR-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 claims 1
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N benzocyclopentane Natural products C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 239000000460 chlorine Chemical group 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- WJDMEHCIRPKRRQ-UHFFFAOYSA-N furo[3,2-c]pyridine Chemical compound N1=CC=C2OC=CC2=C1 WJDMEHCIRPKRRQ-UHFFFAOYSA-N 0.000 claims 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- SMZMHUCIDGHERP-UHFFFAOYSA-N thieno[2,3-b]pyridine Chemical compound C1=CN=C2SC=CC2=C1 SMZMHUCIDGHERP-UHFFFAOYSA-N 0.000 claims 1
- GDQBPBMIAFIRIU-UHFFFAOYSA-N thieno[2,3-c]pyridine Chemical compound C1=NC=C2SC=CC2=C1 GDQBPBMIAFIRIU-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024173357A JP2025013344A (ja) | 2019-09-16 | 2024-10-02 | Ｉｌ－１７ａモジュレーターおよびその使用 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962901249P | 2019-09-16 | 2019-09-16 | |
| US62/901,249 | 2019-09-16 | ||
| US16/783,268 US11447468B2 (en) | 2019-02-06 | 2020-02-06 | IL-17 ligands and uses thereof |
| US16/783,268 | 2020-02-06 | ||
| PCT/US2020/016925 WO2020163554A1 (en) | 2019-02-06 | 2020-02-06 | Il-17a modulators and uses thereof |
| USPCT/US2020/016925 | 2020-02-06 | ||
| US202063061719P | 2020-08-05 | 2020-08-05 | |
| US63/061,719 | 2020-08-05 | ||
| PCT/US2020/050924 WO2021055376A1 (en) | 2019-09-16 | 2020-09-15 | Il-17a modulators and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024173357A Division JP2025013344A (ja) | 2019-09-16 | 2024-10-02 | Ｉｌ－１７ａモジュレーターおよびその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022547617A JP2022547617A (ja) | 2022-11-14 |
| JP2022547617A5 JP2022547617A5 (https=) | 2024-01-05 |
| JPWO2021055376A5 true JPWO2021055376A5 (https=) | 2024-01-05 |
| JP7566889B2 JP7566889B2 (ja) | 2024-10-15 |
Family
ID=74884681
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022516442A Active JP7566889B2 (ja) | 2019-09-16 | 2020-09-15 | Ｉｌ－１７ａモジュレーターおよびその使用 |
| JP2024173357A Pending JP2025013344A (ja) | 2019-09-16 | 2024-10-02 | Ｉｌ－１７ａモジュレーターおよびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024173357A Pending JP2025013344A (ja) | 2019-09-16 | 2024-10-02 | Ｉｌ－１７ａモジュレーターおよびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US11274094B2 (https=) |
| EP (1) | EP4031534A1 (https=) |
| JP (2) | JP7566889B2 (https=) |
| KR (1) | KR20220101075A (https=) |
| CN (1) | CN115103835B (https=) |
| AU (2) | AU2020348685B2 (https=) |
| BR (1) | BR112022004802A2 (https=) |
| CA (1) | CA3154608A1 (https=) |
| IL (1) | IL291345B2 (https=) |
| MX (1) | MX2022003166A (https=) |
| WO (1) | WO2021055376A1 (https=) |
| ZA (1) | ZA202203580B (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI839461B (zh) | 2019-02-06 | 2024-04-21 | 美商戴斯阿爾法股份有限公司 | Il-17a調節物及其用途 |
| IL291345B2 (en) | 2019-09-16 | 2024-04-01 | Dice Alpha Inc | Il-17a modulators and uses thereof |
| MX2024000504A (es) * | 2021-07-09 | 2024-04-05 | Dice Alpha Inc | Moduladores de il-17a basados en fenilacetamida y usos de los mismos. |
| WO2023025783A1 (en) | 2021-08-23 | 2023-03-02 | Leo Pharma A/S | Small molecule modulators of il-17 |
| CN113896712B (zh) * | 2021-11-12 | 2024-04-09 | 华东理工大学 | 含环类氨基酸的二酰胺类化合物 |
| WO2023111181A1 (en) | 2021-12-16 | 2023-06-22 | Leo Pharma A/S | Small molecule modulators of il-17 |
| US20250177383A1 (en) | 2022-02-25 | 2025-06-05 | Dice Alpha, Inc. | Di-cyclopropyl based il-17a modulators and uses thereof |
| WO2023166172A1 (en) | 2022-03-04 | 2023-09-07 | Leo Pharma A/S | Small molecule modulators of il-17 |
| TW202430165A (zh) | 2022-12-02 | 2024-08-01 | 丹麥商理奧藥品公司 | Il-17之小分子調節劑 |
| WO2024208228A1 (en) * | 2023-04-03 | 2024-10-10 | Nuphase Therapeutics (Hangzhou) Limited., Co. | Novel compounds, compositions comprising the same and uses thereof |
| CN121079298A (zh) * | 2023-05-12 | 2025-12-05 | 上海翰森生物医药科技有限公司 | 噻唑类衍生物抑制剂、其制备方法和应用 |
| EP4713318A2 (en) * | 2023-05-18 | 2026-03-25 | Ascletis Pharma (China) Co., Limited | Small molecule modulators of il-17a, methods of making and methods of using thereof |
| WO2025077732A1 (en) * | 2023-10-09 | 2025-04-17 | Shenzhen Ionova Life Science Co., Ltd. | Novel interleukin-17 inhibtors |
| WO2025080986A1 (en) * | 2023-10-13 | 2025-04-17 | Quantx Biosciences Us, Inc. | Amide compounds |
| WO2025131062A1 (zh) * | 2023-12-21 | 2025-06-26 | 江苏恒瑞医药股份有限公司 | 烯烃类化合物、其制备方法及其在医药上的应用 |
| WO2025201532A1 (en) * | 2024-03-28 | 2025-10-02 | Nuphase Therapeutics (Shanghai) Limited., Co. | Novel pegylation compounds, compositions comprising the same and uses thereof |
| WO2025201533A1 (en) * | 2024-03-28 | 2025-10-02 | Nuphase Therapeutics (Shanghai) Limited., Co. | Novel acidic compounds, compositions comprising the same and uses thereof |
| WO2025209395A1 (en) * | 2024-04-03 | 2025-10-09 | Innocare Pharma Inc. | Il-17 modulators and used thereof |
| WO2026021539A1 (zh) * | 2024-07-24 | 2026-01-29 | 深圳信立泰药业股份有限公司 | 双环il-17a/f抑制剂及其制备方法与应用 |
| WO2026040422A1 (en) * | 2024-08-19 | 2026-02-26 | Shenzhen Ionova Life Science Co., Ltd. | Novel interleukin-17 inhibtors |
| WO2026077367A1 (en) * | 2024-10-09 | 2026-04-16 | Foshan Ionova Biotherapeutics Co., Inc. | Novel interleukin-17 inhibtors |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| US4044126A (en) | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
| GB1429184A (en) | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| USRE28819E (en) | 1972-12-08 | 1976-05-18 | Syntex (U.S.A.) Inc. | Dialkylated glycol compositions and medicament preparations containing same |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4358603A (en) | 1981-04-16 | 1982-11-09 | Syntex (U.S.A.) Inc. | Acetal stabilized prostaglandin compositions |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| HU196714B (en) | 1984-10-04 | 1989-01-30 | Monsanto Co | Process for producing non-aqueous composition comprising somatotropin |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
| IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US6010715A (en) | 1992-04-01 | 2000-01-04 | Bertek, Inc. | Transdermal patch incorporating a polymer film incorporated with an active agent |
| US6024975A (en) | 1992-04-08 | 2000-02-15 | Americare International Diagnostics, Inc. | Method of transdermally administering high molecular weight drugs with a polymer skin enhancer |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
| US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
| US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
| CN1087725C (zh) | 1994-03-25 | 2002-07-17 | 同位素技术有限公司 | 用氘代方法增强药物效果 |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
| US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
| US5983134A (en) | 1995-04-23 | 1999-11-09 | Electromagnetic Bracing Systems Inc. | Electrophoretic cuff apparatus drug delivery system |
| US6316652B1 (en) | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
| AU6242096A (en) | 1995-06-27 | 1997-01-30 | Takeda Chemical Industries Ltd. | Method of producing sustained-release preparation |
| US6167301A (en) | 1995-08-29 | 2000-12-26 | Flower; Ronald J. | Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| TW345603B (en) | 1996-05-29 | 1998-11-21 | Gmundner Fertigteile Gmbh | A noise control device for tracks |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| US5985317A (en) | 1996-09-06 | 1999-11-16 | Theratech, Inc. | Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents |
| HUP0000116A3 (en) | 1996-10-01 | 2000-08-28 | Stanford Res Inst Int | Taste-masked microcapsule compositions and methods of manufacture |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| DE69730093T2 (de) | 1996-10-31 | 2006-07-20 | Takeda Pharmaceutical Co. Ltd. | Zubereitung mit verzögerter Freisetzung |
| US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
| WO1998027980A2 (en) | 1996-12-20 | 1998-07-02 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US5860957A (en) | 1997-02-07 | 1999-01-19 | Sarcos, Inc. | Multipathway electronically-controlled drug delivery system |
| US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
| US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
| US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
| WO1999021537A1 (fr) | 1997-10-28 | 1999-05-06 | Bando Chemical Industries, Ltd. | Feuille de timbre cutane et procede de production d'une feuille de base pour timbre |
| CA2316273A1 (en) | 1998-01-16 | 1999-07-22 | Takeda Chemical Industries, Ltd. | Sustained-release composition, method of its production and use thereof |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
| KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
| US6256533B1 (en) | 1999-06-09 | 2001-07-03 | The Procter & Gamble Company | Apparatus and method for using an intracutaneous microneedle array |
| US6261595B1 (en) | 2000-02-29 | 2001-07-17 | Zars, Inc. | Transdermal drug patch with attached pocket for controlled heating device |
| US20060270730A1 (en) | 2003-08-07 | 2006-11-30 | Andreas Katopodis | Histone deacetylase inhibitors as immunosuppressants |
| CA2538237A1 (en) | 2003-09-10 | 2005-03-24 | Map Pharmaceuticals, Inc. | Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation |
| EP2403531A4 (en) * | 2009-03-05 | 2013-02-27 | Abbott Lab | IL-17 BINDING PROTEINS |
| US9284283B2 (en) * | 2012-02-02 | 2016-03-15 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating IL-17 |
| WO2014066726A2 (en) * | 2012-10-26 | 2014-05-01 | Ensemble Therapeutics Corporation | Compounds for modulating il-17 |
| ES2950424T3 (es) * | 2013-07-03 | 2023-10-09 | Takeda Pharmaceuticals Co | Compuesto de amida |
| UA117941C2 (uk) * | 2013-12-05 | 2018-10-25 | Лід Фарма Холдінг Б.В. | МОДУЛЯТОРИ ROR-ГAMMA (RORγ) |
| EP3101006A1 (en) * | 2015-06-05 | 2016-12-07 | Lead Pharma Cel Models IP B.V. | Ror gamma (rory) modulators |
| WO2018030550A1 (en) * | 2016-08-09 | 2018-02-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds with an ror(gamma)t modulating activity |
| EP3523279A1 (en) * | 2016-10-10 | 2019-08-14 | Bristol-Myers Squibb Company | Tricyclic sulfones as ror gamma modulators |
| WO2019163945A1 (ja) * | 2018-02-22 | 2019-08-29 | 学校法人東海大学 | Ｉｌ－１７ａ活性阻害剤およびその用途 |
| GB201820166D0 (en) | 2018-12-11 | 2019-01-23 | Ucb Biopharma Sprl | Therapeutic agents |
| TWI839461B (zh) | 2019-02-06 | 2024-04-21 | 美商戴斯阿爾法股份有限公司 | Il-17a調節物及其用途 |
| IL291345B2 (en) | 2019-09-16 | 2024-04-01 | Dice Alpha Inc | Il-17a modulators and uses thereof |
-
2020
- 2020-09-15 IL IL291345A patent/IL291345B2/en unknown
- 2020-09-15 WO PCT/US2020/050924 patent/WO2021055376A1/en not_active Ceased
- 2020-09-15 AU AU2020348685A patent/AU2020348685B2/en active Active
- 2020-09-15 MX MX2022003166A patent/MX2022003166A/es unknown
- 2020-09-15 BR BR112022004802A patent/BR112022004802A2/pt unknown
- 2020-09-15 KR KR1020227012236A patent/KR20220101075A/ko active Pending
- 2020-09-15 JP JP2022516442A patent/JP7566889B2/ja active Active
- 2020-09-15 CA CA3154608A patent/CA3154608A1/en active Pending
- 2020-09-15 EP EP20775787.3A patent/EP4031534A1/en active Pending
- 2020-09-15 CN CN202080079537.5A patent/CN115103835B/zh active Active
- 2020-12-11 US US17/118,947 patent/US11274094B2/en active Active
-
2022
- 2022-01-27 US US17/585,974 patent/US12421212B2/en active Active
- 2022-03-28 ZA ZA2022/03580A patent/ZA202203580B/en unknown
- 2022-12-28 US US18/090,275 patent/US20230145481A1/en not_active Abandoned
- 2022-12-28 US US18/090,319 patent/US20230141212A1/en not_active Abandoned
-
2024
- 2024-10-02 JP JP2024173357A patent/JP2025013344A/ja active Pending
-
2026
- 2026-02-12 AU AU2026201044A patent/AU2026201044A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021055376A5 (https=) | ||
| JP4714686B2 (ja) | 新規のγ−セクレターゼ阻害剤 | |
| DE69431056T2 (de) | Substituierte oxazolyl-derivate zur behandlung von entzündungen | |
| EP0207453B1 (en) | Heterocyclic substituted-phenoxyalkyl-isoxazoles and-furans, their preparation and use as antiviral agents | |
| AU655924B2 (en) | Thiophene sulfonamides useful as carbonic anydrase inhibitors | |
| AU2007229492B2 (en) | Benzothiazoles having histamine H3 receptor activity | |
| JP2019536785A5 (https=) | ||
| AU2008326385B2 (en) | Substituted benzoazole PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disorders | |
| EP1041982A1 (en) | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | |
| CZ299995A3 (en) | Novel thiazolidinediones and medicaments containing thereof | |
| MX2008013400A (es) | Derivado de azolcarboxamida. | |
| HRP20151126T1 (hr) | DERIVATI IMIDAZO[2,1-b][1,3,4]TIADIAZOLA | |
| AU2022202916A1 (en) | Polycyclic amines as opioid receptor modulators | |
| NZ209209A (en) | Substituted phenyl-aliphatic isoxazole derivatives and pharmaceutical compositions | |
| US5264451A (en) | Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones | |
| DK185789D0 (da) | Fremgangsmaade til fremstilling af optisk aktive 3-(carbonhydridsulfonyloxy)thiolaner eller deres 1-oxider og mellemprodukter ved fremgangsmaaden | |
| JPWO2023283453A5 (https=) | ||
| US5538966A (en) | Carbonic anhydrase inhibitors | |
| JPS62138492A (ja) | 新規化合物、その製法及びそれを含む医薬組成物 | |
| EP1119570B1 (en) | Tricyclic delta3-piperidines as pharmaceuticals | |
| JPH0755937B2 (ja) | オキサ（チア）ゾリジン誘導体その製造方法及び殺ダニ剤 | |
| IE40755B1 (en) | Process for the preparation of s-triazolo (3,4-b)benzothiazoles | |
| GB1033167A (en) | 6-phenyl dihydro-oxadiazines and method for their preparation | |
| IE801761L (en) | Pharmaceutical compositions | |
| JPWO2021176366A5 (https=) |